Verastem Inc (NASDAQ:VSTM) – Equities researchers at B. Riley issued their FY2017 earnings per share estimates for shares of Verastem in a research report issued to clients and investors on Thursday. B. Riley analyst G. Zavoico anticipates that the biopharmaceutical company will post earnings of ($1.72) per share for the year. B. Riley has a “Buy” rating and a $15.00 price objective on the stock. B. Riley also issued estimates for Verastem’s Q4 2017 earnings at ($0.39) EPS, Q1 2018 earnings at ($0.37) EPS, Q2 2018 earnings at ($0.37) EPS, Q3 2018 earnings at ($0.38) EPS, Q4 2018 earnings at ($0.34) EPS, FY2018 earnings at ($1.45) EPS, FY2019 earnings at ($0.94) EPS, FY2020 earnings at ($0.12) EPS, FY2021 earnings at $0.58 EPS and FY2022 earnings at $1.58 EPS.
VSTM has been the topic of a number of other reports. Oppenheimer restated a “buy” rating and issued a $15.00 target price on shares of Verastem in a research note on Sunday, December 10th. Cantor Fitzgerald set a $17.00 target price on shares of Verastem and gave the stock a “buy” rating in a research note on Sunday, December 10th. Cann reiterated a “buy” rating and set a $13.00 price objective on shares of Verastem in a research note on Friday, January 26th. ValuEngine downgraded shares of Verastem from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research downgraded shares of Verastem from a “hold” rating to a “sell” rating in a research note on Wednesday, February 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Verastem presently has a consensus rating of “Buy” and a consensus price target of $10.14.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC boosted its stake in shares of Verastem by 92.8% during the fourth quarter. Millennium Management LLC now owns 357,615 shares of the biopharmaceutical company’s stock valued at $1,098,000 after purchasing an additional 172,166 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of Verastem by 133.7% during the fourth quarter. Two Sigma Investments LP now owns 261,771 shares of the biopharmaceutical company’s stock valued at $804,000 after purchasing an additional 149,744 shares in the last quarter. Two Sigma Advisers LP bought a new position in shares of Verastem during the fourth quarter valued at approximately $231,000. BVF Inc. IL bought a new position in shares of Verastem during the fourth quarter valued at approximately $6,908,000. Finally, Stonepine Capital Management LLC purchased a new stake in Verastem during the fourth quarter valued at approximately $691,000. Hedge funds and other institutional investors own 33.22% of the company’s stock.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.